Medable

03/13/2026

The Medable Platform 🤝 Keeping studies on track.

03/12/2026

The journey from discovery to treatment is one of the hardest challenges in healthcare. 🔬

Today at the Miami CEO event, Medable CEO Dr. Michelle Longmire is joining the panel “Translating Science into Medicine” to explore how leaders across the ecosystem can accelerate that journey and deliver therapies to patients sooner.

Speakers:
- Anish Bhatnagar, CEO, Soleno Therapeutics
- Bill Hait, Chief Scientific Advisor, AACR; former Global Head, Janssen R&D
- Michelle Longmire, CEO, Medable
- Sondra Neale Smyrnios, SVP, Clinical & Technical Operations, Newleos
- Moderator: Jeremy Levin, Chair, Ovid Therapeutics

Hosted by Longwood Healthcare Leaders.

Learn more here: https://www.longwoodhealthcareleaders.com/miamiceo
________

03/10/2026

Our CRA Agent demo has multiple mic-drop moments 😉 🫳 🎤. Send us a DM to see it for yourself 🚀 .

03/04/2026

"I hope in the future we abolish phrases like 'male-dominated.'"
As we enter International Women's Month and reflect on this year’s theme, 'leading the change,' the women of Medable shared what they hope the future holds for the next generation—professionally, personally, and beyond.

Take a listen below! ⬇️⬇️
________

03/04/2026

Cell & gene therapies have delivered life-changing outcomes, but their long-term success depends on follow-up models that are not meeting the needs of participants and are no longer fit for purpose.

Traditional long-term follow-up (LTFU) studies place heavy logistical burdens on patients and sites, leading to low participation rates and knowledge gaps. At least 20% of CAR T-cell therapy patients drop out of studies entirely, and 80% drop by year 5.

It’s time to rethink the model.

This session with Medable's CMO, Dr. Pamela Tenaerts, explores a digital-first approach to LTFU designed to sustain participant engagement, reduce attrition, and maintain scientific and regulatory rigor over time.

Join us tomorrow at Endpoints News' C> Summit to learn how remote and hybrid interaction, seamless transitions from parent trials, and patient-centered data capture can strengthen safety monitoring, improve data quality, and better reflect the real-world impact of advanced therapies.

Register here: https://events.endpoints.news/cgday26
________

Cell and gene therapy has some wind beneath its sails. New regulatory frameworks from the Food and Drug Administration could help streamline development and manufacturing. Large pharma companies are investing in cell therapy start-ups. Will these shifts help the field overcome some long-standing hur...

03/03/2026

"Decentralized trial tools are settling into routine use as sponsors and sites apply them selectively to address protocol-specific operational needs," agree Medable's Dr. Pamela Tenaerts and Tufts CSDD's Ken Getz.

This will be a main topic of conversation at tomorrow's Innovation Evidence Workshop, hosted by Tufts CSDD & Medable.

This event will bring together pharmaceutical R&D executives and regulatory representatives to examine the use and impact of virtual and remote clinical trial technologies, experiences with agentic-AI-enabled processes supporting clinical research, and the challenges and opportunities of deploying transformative innovations while adhering to ICH E6 R3 guidelines.

Get a glimpse of the insights shared tomorrow from Tenaerts and Getz here: https://insights.citeline.com/pink-sheet/r-and-d/clinical-trials/decentralized-trials-are-on-classic-path-of-normalization-while-solving-real-problems-BHMZVJNWBVBTXL4EKLOYCCR5CM/
________

Decentralized trial tools are settling into routine use as sponsors and sites apply them selectively to address protocol-specific operational needs, say Pamela Tenaerts and Kenneth Getz.

03/03/2026

Experience is everything in oncology trials for patients, sites, and investigators, especially in an environment that demands precision, speed, and full transparency. In this live demonstration, Rana Khan will showcase an end-to-end eCOA workflow from both the patient and site perspective during an active study, highlighting how symptom reporting and episodic events are captured and managed in real time.

The session concludes with a preview of Medable's PI Summary Agent, an AI assistant embedded within the eCOA workflow, supporting the PI in ongoing review and signature without replacing PI oversight or blocking site or participant activities.

👉 Secure your spot at tomorrow's event here: https://event.on24.com/wcc/r/5193469/3CF9FA53C3DA758A348D93760740F53C?partnerref=li-show-ctech-021126
________

03/02/2026

Did you know that manual document reconciliation between trial systems consumes at least one-third of clinical data managers' and clinical research associates’ time?

This means your highly trained professionals are spending their days chasing files between platforms rather than moving science forward.

Medable’s TMF Agent takes on the high-volume work of organizing and filing trial documents across studies. Your team reviews, approves, stays in control where it matters, and gets their time back.

That shift is a game changer and frees up real strategic capacity.

DM this account to learn more! 📥
________

02/27/2026

Let’s ask a trick question. Do you think your organization’s data is ready for AI or AI agents?

In a landscape defined by speed, complexity, and constant change, progress doesn’t come from waiting for ideal conditions. It comes from taking the first step. And with agentic AI, you can start now.

Learn more here: https://www.medable.com/knowledge-center/blog-compounding-interest-why-good-enough-data-is-good-enough-for-agentic-ai
________

Agentic AI doesn’t require perfect clinical trial data. Learn why “good enough” data can already drive real impact for sponsors and CROs.

02/24/2026

Assessment and instrument translations can bring global study deployment to a grinding halt. 🫠

Back-and-forth files. Version confusion. Validation headaches.
It doesn't have to be this way.

Rana Khan demos below how we built localization into eCOA the right way.
________

02/20/2026

If your eCOA RFI is just a feature checklist, you’re setting yourself up for problems later.
“Do you support X?” is easy to answer. “Prove your uptime, implementation track record, and audit history” is harder.

The difference shows up mid-study, when switching vendors isn’t an option.

Here’s how to write an RFI that protects you before you sign: https://www.medable.com/knowledge-center/blog-ecoa-standards-and-kpis-to-include-in-your-next-rfi
_________

Strengthen your next eCOA RFI with performance-driven standards and measurable KPIs and to evaluate vendors based on outcomes instead of promises.

02/18/2026

Most “AI in clinical trials” is just analysis after the fact. What if it could actually move the work forward?

Agents that understand messy data. Agents that unify it across systems. Agents that take action.

That’s what Medable’s Agent Studio is built for. Fiachra Matthews breaks it down below.
________